CAESAREA, Israel, March 25, 2026
IceCure Medical has reported positive five-year top-line results from its ICESECRET clinical trial, demonstrating high recurrence-free survival rates in kidney cancer patients treated with its ProSense® cryoablation system. The study highlights 89.4% recurrence-free rates in patients with tumors ≤3 cm and 83.9% in the overall population, reinforcing the potential of minimally invasive cryoablation as an effective alternative to surgical tumor removal.
Strong Long-Term Outcomes in Kidney Cancer Treatment
The ICESECRET study evaluated the safety and efficacy of ProSense® cryoablation technology in patients with small renal masses (SRMs), a growing clinical challenge due to increasing detection rates and the need for less invasive treatment options. The trial enrolled 114 patients, with 112 evaluated at a median follow-up of four years, providing robust long-term data on treatment outcomes.
The results demonstrated that 83.9% of patients remained recurrence-free at the median follow-up period, indicating strong durability of response. Notably, in a subgroup of patients with tumors ≤3 cm and no prior kidney cancer, recurrence-free rates reached 89.4%, highlighting the effectiveness of the therapy in early-stage disease. A small proportion of patients required repeat procedures, further supporting the feasibility of cryoablation as a repeatable and manageable intervention.
These findings underscore the clinical value of minimally invasive therapies that can achieve outcomes comparable to surgical approaches while reducing procedural risks and recovery time.
Advertisement
Minimally Invasive Technology Drives Clinical Innovation
ProSense® is a liquid nitrogen-based cryoablation system designed to destroy tumors by freezing them, offering a precise, nephron-sparing treatment option for patients who may not be suitable candidates for surgery. The technology enables targeted tumor destruction while preserving surrounding healthy tissue, which is particularly important in maintaining kidney function.
The system has already received regulatory approvals in the United States, Europe, and other global markets for the treatment of kidney tumors, as well as applications in breast, lung, liver, and bone cancers. Its portable design, reduced procedural complexity, and shorter recovery times make it an attractive option for both clinicians and patients seeking less invasive treatment alternatives.
The ICESECRET trial, conducted across multiple clinical centers in Israel, further validates the safety and effectiveness of cryoablation under real-world conditions, supporting its broader adoption in oncology practice.
Growing Demand for Non-Surgical Cancer Therapies
The rising incidence of kidney cancer globally, with hundreds of thousands of new cases diagnosed annually, has intensified the demand for effective, minimally invasive treatment solutions. Small renal masses are increasingly detected through advanced imaging technologies, particularly in elderly patients and those with comorbidities who may not tolerate surgery.
Cryoablation offers a compelling alternative by reducing surgical risks, minimizing hospital stays, and improving patient recovery outcomes, while maintaining strong oncological control. The long-term data from the ICESECRET study highlight the potential for cryoablation to become a standard-of-care option in selected patient populations, particularly those requiring nephron-sparing approaches.
The company expects to present detailed findings from the study at the European Conference on Interventional Oncology (ECIO) 2026, further contributing to the growing body of evidence supporting image-guided, minimally invasive cancer therapies.
The five-year results from IceCure’s ICESECRET trial provide compelling evidence supporting the long-term efficacy and safety of ProSense® cryoablation technology in kidney cancer treatment. With high recurrence-free survival rates, favorable patient outcomes, and strong clinical validation, the technology represents a significant advancement in minimally invasive oncology care.
As healthcare systems continue to prioritize patient-centered, less invasive treatment approaches, cryoablation is positioned to play an increasingly important role in cancer management. IceCure’s continued innovation and clinical progress reinforce its position as a key player in advancing next-generation medical technologies for oncology treatment.
Source: IceCure press release
